ECSP077881A - SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATION OF THE SAME, PROCEDURE FOR PREPARING SUCH COMPOSITION BY DIRECT COMPRESSION, PHARMACEUTICAL FORMULATIONS THAT - Google Patents

SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATION OF THE SAME, PROCEDURE FOR PREPARING SUCH COMPOSITION BY DIRECT COMPRESSION, PHARMACEUTICAL FORMULATIONS THAT

Info

Publication number
ECSP077881A
ECSP077881A ECSP077881A ECSP077881A EC SP077881 A ECSP077881 A EC SP077881A EC SP077881 A ECSP077881 A EC SP077881A EC SP077881 A ECSP077881 A EC SP077881A
Authority
EC
Ecuador
Prior art keywords
composition
preparing
direct compression
ibandronic acid
pharmaceutically acceptable
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Andrea Gabriela Tizado
Cecilia Sterpetti
Fernando Rodolfo Campa
Original Assignee
Laboratorio Elea S A C I F Y A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Elea S A C I F Y A filed Critical Laboratorio Elea S A C I F Y A
Publication of ECSP077881A publication Critical patent/ECSP077881A/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica sólida en forma de dosificación unitaria para administración oral de ácido ibandrónico, obtenida mediante un proceso de compresión directa, que comprende 30 a 37% en peso de ácido ibandrónico o una sal o un hidrato farmacéuticamente aceptable del mismo, al menos un diluyente en una cantidad de aproximadamente 55 a 65% en peso, al menos un agente desintegrante en una cantidad de aproximadamente 0,5 a 1,5% en peso y al menos un lubricante en una cantidad de aproximadamente 4,5 a 5,5% en peso. La invención también comprende un proceso de compresión directa para preparar dichas composiciones así como las formulaciones farmacéuticas recubiertas que comprenden dichas composiciones y un proceso para preparar dichas formulaciones farmacéuticas recubiertas.The present invention relates to a solid pharmaceutical composition in unit dosage form for oral administration of ibandronic acid, obtained by a direct compression process, comprising 30 to 37% by weight of ibandronic acid or a pharmaceutically acceptable salt or hydrate of the same, at least one diluent in an amount of about 55 to 65% by weight, at least one disintegrating agent in an amount of about 0.5 to 1.5% by weight and at least one lubricant in an amount of about 4, 5 to 5.5% by weight. The invention also comprises a direct compression process for preparing said compositions as well as coated pharmaceutical formulations comprising said compositions and a process for preparing said coated pharmaceutical formulations.

ECSP077881 2006-11-09 2007-11-06 SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATION OF THE SAME, PROCEDURE FOR PREPARING SUCH COMPOSITION BY DIRECT COMPRESSION, PHARMACEUTICAL FORMULATIONS THAT ECSP077881A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP060104910 AR058512A1 (en) 2006-11-09 2006-11-09 SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF IBANDRONIC ACID OR A SALT OR A PHARMACEUTICALLY ACCEPTABLE HYDRATION OF THE SAME, PREPARATION PROCEDURE FOR THIS COMPOSITION BY DIRECT COMPRESSION, PHARMACEUTICAL FORMULATIONS THAT PREPARE AND PROCEDURE TO PREPARE

Publications (1)

Publication Number Publication Date
ECSP077881A true ECSP077881A (en) 2008-06-30

Family

ID=39059286

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP077881 ECSP077881A (en) 2006-11-09 2007-11-06 SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATION OF THE SAME, PROCEDURE FOR PREPARING SUCH COMPOSITION BY DIRECT COMPRESSION, PHARMACEUTICAL FORMULATIONS THAT

Country Status (9)

Country Link
AR (1) AR058512A1 (en)
BR (1) BRPI0704025A (en)
CL (1) CL2007003210A1 (en)
CO (1) CO5930065A1 (en)
DO (1) DOP2007000134A (en)
EC (1) ECSP077881A (en)
MX (1) MX2007014056A (en)
PE (1) PE20081343A1 (en)
UY (1) UY30697A1 (en)

Also Published As

Publication number Publication date
CL2007003210A1 (en) 2008-03-14
UY30697A1 (en) 2008-02-29
BRPI0704025A (en) 2008-07-01
MX2007014056A (en) 2009-02-19
DOP2007000134A (en) 2008-06-15
CO5930065A1 (en) 2008-06-27
PE20081343A1 (en) 2008-09-24
AR058512A1 (en) 2008-02-06

Similar Documents

Publication Publication Date Title
FI3504187T3 (en) Use of pridopidine for treating functional decline
BRPI0922796A2 (en) PHARMACEUTICAL TABLET FOR ORAL ADMINISTRATION AND MANUFACTURING METHOD
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
MX338685B (en) Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin.
MX2016010213A (en) Novel pharmaceutical formulations.
UY35624A (en) USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE
BR112012021681A2 (en) rifaximin powder, process for preparing it and controlled release compositions containing said rifaximin useful for obtaining a long lasting effect.
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
AR070025A1 (en) USE OF DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF COCLEAR TINNITUS AND PHARMACEUTICAL COMPOSITION
MX379946B (en) Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
UY32599A (en) ABT-263 SOLID ORAL FORMULATION
AR079639A1 (en) COMPOSITION OF ANTI-EROSIVE TOOTHPASTE
GT200600096A (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
EA201291410A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINO-5-FTOR-3- [6- (4-METHILPIPERAZIN-1-IL) -1H-BENZIMIDAZOLE-2-IL] -1H-HINOLIN-2-SHE LOCTOT MONOHYTHA-2-IL] -1H-HINOLIN-2-SH-LYTOTOL-2-IL--1-IL-HYNOLIN-2-SH
AR107391A1 (en) FORMULATIONS / COMPOSITIONS THAT INCLUDE A BTK INHIBITOR
CO6270217A2 (en) GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN
BRPI0816798A2 (en) compound, pharmaceutical composition, methods for inhibiting the action of glycogen synthase kinase-3, and for treating, preventing or ameliorating a disease, use of a compound, and article of manufacture
AR095159A2 (en) A PHARMACEUTICAL COMPOSITION IN THE FORM OF A CAPSULE FOR ORAL ADMINISTRATION
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
BR112012022209A2 (en) pharmaceutical compositions comprising monoterpenes
MX2024007642A (en) Use of riluzole oral disintigrating tablets for treating diseases.
BR112015014137A2 (en) fexofenadine solid unit and process for preparing it
UA94036C2 (en) Bendamustine pharmaceutical compositions for lyophilisation
ECSP077881A (en) SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATION OF THE SAME, PROCEDURE FOR PREPARING SUCH COMPOSITION BY DIRECT COMPRESSION, PHARMACEUTICAL FORMULATIONS THAT